Vandortuzumab vedotin

Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]

Vandortuzumab vedotin
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetSTEAP1
Clinical data
Other namesRG7450
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6608H10168N1756O2076S44
Molar mass148838.89 g·mol−1

This drug was developed by Genentech/Roche. Development was discontinued in 2017.[3]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.